Literature DB >> 26419959

MicroRNA MIR21 and T Cells in Colorectal Cancer.

Kosuke Mima1, Reiko Nishihara2, Jonathan A Nowak3, Sun A Kim1, Mingyang Song4, Kentaro Inamura1, Yasutaka Sukawa1, Atsuhiro Masuda1, Juhong Yang1, Ruoxu Dou1, Katsuhiko Nosho5, Hideo Baba6, Edward L Giovannucci7, Michaela Bowden1, Massimo Loda8, Marios Giannakis9, Adam J Bass10, Glenn Dranoff11, Gordon J Freeman1, Andrew T Chan12, Charles S Fuchs13, Zhi Rong Qian14, Shuji Ogino15.   

Abstract

The complex interactions between colorectal neoplasia and immune cells in the tumor microenvironment remain to be elucidated. Experimental evidence suggests that microRNA MIR21 (miR-21) suppresses antitumor T-cell-mediated immunity. Thus, we hypothesized that tumor MIR21 expression might be inversely associated with T-cell density in colorectal carcinoma tissue. Using 538 rectal and colon cancer cases from the Nurses' Health Study and the Health Professionals Follow-up Study, we measured tumor MIR21 expression by a quantitative reverse-transcription PCR assay. Densities of CD3(+), CD8(+), CD45RO (PTPRC)(+), and FOXP3(+) cells in tumor tissue were determined by tissue microarray immunohistochemistry and computer-assisted image analysis. Ordinal logistic regression analysis was conducted to assess the association of MIR21 expression (ordinal quartiles as a predictor variable) with T-cell density (ordinal quartiles as an outcome variable), adjusting for tumor molecular features, including microsatellite instability; CpG island methylator phenotype; KRAS, BRAF, and PIK3CA mutations; and LINE-1 methylation. We adjusted the two-sided α level to 0.012 for multiple hypothesis testing. Tumor MIR21 expression was inversely associated with densities of CD3(+) and CD45RO(+) cells (Ptrend < 0.0005). The multivariate odds ratio of the highest versus lowest quartile of MIR21 for a unit increase in quartile categories of CD3(+) or CD45RO(+) cells was 0.44 [95% confidence interval (CI), 0.28 to 0.68] or 0.41 (95% CI, 0.26-0.64), respectively. Our data support a possible role of tumor epigenetic deregulation by noncoding RNA in suppressing the antitumor T-cell-mediated adaptive immune response and suggest MIR21 as a potential target for immunotherapy and prevention in colorectal cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26419959      PMCID: PMC4703429          DOI: 10.1158/2326-6066.CIR-15-0084

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  50 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

2.  PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis.

Authors:  Matteo Fassan; Marco Pizzi; Luciano Giacomelli; Claudia Mescoli; Kathrin Ludwig; Salvatore Pucciarelli; Massimo Rugge
Journal:  Virchows Arch       Date:  2011-01-29       Impact factor: 4.064

Review 3.  Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field.

Authors:  Shuji Ogino; Andrew T Chan; Charles S Fuchs; Edward Giovannucci
Journal:  Gut       Date:  2010-10-29       Impact factor: 23.059

4.  Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors.

Authors:  Lorenzo F Sempere; Meir Preis; Todd Yezefski; Haoxu Ouyang; Arief A Suriawinata; Asli Silahtaroglu; Jose R Conejo-Garcia; Sakari Kauppinen; Wendy Wells; Murray Korc
Journal:  Clin Cancer Res       Date:  2010-08-03       Impact factor: 12.531

5.  Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21.

Authors:  Rosetta Merline; Kristin Moreth; Janet Beckmann; Madalina V Nastase; Jinyang Zeng-Brouwers; José Guilherme Tralhão; Patricia Lemarchand; Josef Pfeilschifter; Roland M Schaefer; Renato V Iozzo; Liliana Schaefer
Journal:  Sci Signal       Date:  2011-11-15       Impact factor: 8.192

6.  MicroRNA-21 and PDCD4 expression in colorectal cancer.

Authors:  K H Chang; N Miller; E A H Kheirelseid; H Ingoldsby; E Hennessy; C E Curran; S Curran; M J Smith; M Regan; O J McAnena; M J Kerin
Journal:  Eur J Surg Oncol       Date:  2011-05-04       Impact factor: 4.424

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Authors:  Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

9.  Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells.

Authors:  Natsumi Irahara; Katsuhiko Nosho; Yoshifumi Baba; Kaori Shima; Neal I Lindeman; Aditi Hazra; Eva S Schernhammer; David J Hunter; Charles S Fuchs; Shuji Ogino
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

10.  Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

Authors:  Xiaoyun Liao; Teppei Morikawa; Paul Lochhead; Yu Imamura; Aya Kuchiba; Mai Yamauchi; Katsuhiko Nosho; Zhi Rong Qian; Reiko Nishihara; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2012-02-22       Impact factor: 12.531

View more
  19 in total

1.  Mucosal cancer-associated microbes and anastomotic leakage after resection of colorectal carcinoma.

Authors:  Kosuke Mima; Yuki Sakamoto; Keisuke Kosumi; Yoko Ogata; Keisuke Miyake; Yukiharu Hiyoshi; Takatsugu Ishimoto; Masaaki Iwatsuki; Yoshifumi Baba; Shiro Iwagami; Yuji Miyamoto; Naoya Yoshida; Shuji Ogino; Hideo Baba
Journal:  Surg Oncol       Date:  2019-11-18       Impact factor: 3.279

2.  MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer.

Authors:  Ruoxu Dou; Reiko Nishihara; Yin Cao; Tsuyoshi Hamada; Kosuke Mima; Atsuhiro Masuda; Yohei Masugi; Yan Shi; Mancang Gu; Wanwan Li; Annacarolina da Silva; Katsuhiko Nosho; Xuehong Zhang; Jeffrey A Meyerhardt; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

3.  MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.

Authors:  Kosuke Mima; Reiko Nishihara; Juhong Yang; Ruoxu Dou; Yohei Masugi; Yan Shi; Annacarolina da Silva; Yin Cao; Mingyang Song; Jonathan Nowak; Mancang Gu; Wanwan Li; Teppei Morikawa; Xuehong Zhang; Kana Wu; Hideo Baba; Edward L Giovannucci; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

Review 4.  Proceedings of the third international molecular pathological epidemiology (MPE) meeting.

Authors:  Peter T Campbell; Timothy R Rebbeck; Reiko Nishihara; Andrew H Beck; Colin B Begg; Alexei A Bogdanov; Yin Cao; Helen G Coleman; Gordon J Freeman; Yujing J Heng; Curtis Huttenhower; Rafael A Irizarry; N Sertac Kip; Franziska Michor; Daniel Nevo; Ulrike Peters; Amanda I Phipps; Elizabeth M Poole; Zhi Rong Qian; John Quackenbush; Harlan Robins; Peter K Rogan; Martha L Slattery; Stephanie A Smith-Warner; Mingyang Song; Tyler J VanderWeele; Daniel Xia; Emily C Zabor; Xuehong Zhang; Molin Wang; Shuji Ogino
Journal:  Cancer Causes Control       Date:  2017-01-17       Impact factor: 2.506

Review 5.  Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

6.  Pan-Cancer Analysis Predicts the Immunological and Prognostic Role of ZC3H12C in KIRC.

Authors:  Yanping Yue; Yumeng Wu; Dakun Zhao; Biao Wu; Xuming Wu; Jibin Liu; Lei Yang; Aiguo Shen
Journal:  Biomed Res Int       Date:  2022-06-26       Impact factor: 3.246

Review 7.  Genomics, Telomere Length, Epigenetics, and Metabolomics in the Nurses' Health Studies.

Authors:  Mary K Townsend; Hugues Aschard; Immaculata De Vivo; Karin B Michels; Peter Kraft
Journal:  Am J Public Health       Date:  2016-07-26       Impact factor: 9.308

Review 8.  Integration of molecular pathology, epidemiology and social science for global precision medicine.

Authors:  Akihiro Nishi; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Andy S Tan; Ichiro Kawachi; Shuji Ogino
Journal:  Expert Rev Mol Diagn       Date:  2015-12-04       Impact factor: 5.225

Review 9.  Insights into the Regulatory Role of Non-coding RNAs in Cancer Metabolism.

Authors:  Fredy O Beltrán-Anaya; Alberto Cedro-Tanda; Alfredo Hidalgo-Miranda; Sandra L Romero-Cordoba
Journal:  Front Physiol       Date:  2016-08-08       Impact factor: 4.566

10.  The NF-κB signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression.

Authors:  Martha L Slattery; Lila E Mullany; Lori Sakoda; Wade S Samowitz; Roger K Wolff; John R Stevens; Jennifer S Herrick
Journal:  J Cancer Res Clin Oncol       Date:  2017-11-29       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.